Navigation Links
Neogen Reports 27% Increase in Quarterly Net Income

LANSING, Mich., March 22, 2011 /PRNewswire/ -- Neogen Corporation (Nasdaq: NEOG) announced today that its net income for the third quarter of FY 2011, which ended Feb. 28, increased 27% from the previous year to $4,943,000 — or to $0.21 per share, compared to the prior year's $0.17 per share.

Third quarter revenues increased 25% to $42,235,000, a record third quarter for the 28-year-old company, compared to the prior year's $33,833,000. Year to date, nine-month revenues increased 27% in the current fiscal year to $129,088,000 from FY 2010's $101,431,000. Current year-to-date net income for the same nine-month period increased 31% to $16,878,000 from $12,887,000 in FY 2010, or to $0.71 per share compared to the prior year's $0.56 per share.

"We are very pleased to report our solid third quarter results, especially when considering the comparison to our outstanding third quarter performance last fiscal year," said James Herbert, Neogen's chief executive officer and chairman. "The fact that we are reporting a significant revenue increase this quarter is a testimony to the diversified nature of Neogen's products, our synergistic acquisition strategy, and our international expansion."

The third quarter was the 72nd consecutive profitable quarter from operations for the company, and the 76th quarter of the past 81 quarters to show increased revenues as compared with the previous year — including the last 24 consecutive quarters.

"Our strong third quarter growth was a mix of the accretive GeneSeek acquisition and solid same-store sales increases," said Lon Bohannon, Neogen's president and chief operating officer. "On the animal safety side, our comprehensive biosecurity marketing effort continues to gain traction as we achieved significant increases in sales of rodenticides, cleaners and disinfectants. We see these products as natural complements to our diagnostics, and as integral components in our overall mission to provide the best available food and animal safety solutions. On the food safety side, our recent internally developed or enhanced diagnostics for dairy antibiotics, foodborne pathogens, and sanitation monitoring all experienced substantial increases in the third quarter."

For the quarter, operating income increased 40% to $8,065,000, and for the first nine months of the company's 2011 fiscal year, Neogen's operating income improved 37% to $27,290,000. Expressed as a percentage of revenues, year-to-date operating income for the current fiscal year improved to 21.1% compared to 19.6% in the prior year.

"As our consolidated balance sheet shows, Neogen continues to generate positive cash flow, and we now have more than $47 million in cash and investments to continue to pursue a wide variety of growth strategies," said Steve Quinlan, Neogen's vice president and chief financial officer. "The quarter's results provide further evidence of Neogen's improving operational efficiencies, as our continuing cost control efforts resulted in a decline in operating expenses as a percentage of revenues during the comparative quarter from 34.6% in 2010 to 29.7% in 2011."

Neogen's Animal Safety Division led the company's third quarter revenue increase, with sales up 53% from $14,115,000 in FY 2010 to $21,601,000 in the current year. For the current quarter, the division recorded organic sales growth of 17%. For the first nine months of FY 2011, the division's sales increased 42% over the prior year to $64,862,000. The April 2010 acquisition of GeneSeek contributed to the division's FY 2011 revenue increase, as the commercial agricultural genetics laboratory continued to exceed internal revenue expectations in its first year under Neogen's ownership. Year to date, the overall Animal Safety Division has recorded organic growth of 10% compared to the prior year.  

Sales of Neogen's extensive line of agricultural cleaners and disinfectants substantially increased in the quarter, led by improving sales into livestock production markets in Central and South America, Asia, and Canada. Neogen's line of BioSentry® biosecurity products and the line of DuPont products distributed by Neogen experienced significant sales increases. A successful sales program helped spur Neogen's rodenticide sales to levels well in excess of prior year quarterly figures. The company's Animal Safety Division also had large increases in its sales of life science diagnostics and veterinary instruments.  

Despite a difficult comparison with the exceptional performance of the prior year's third quarter, the Lansing, Mich.-based Food Safety Division's third quarter revenues increased from $19,718,000 in FY 2010 to $20,634,000 in the current year. In the third quarter of the previous fiscal year, sales of Neogen's food safety diagnostics spiked as the company helped corn producers and processors address a widespread vomitoxin outbreak in the United States. In the third quarter of FY 2011, Neogen's sales of vomitoxin kits returned to pre-outbreak levels as the corn crop has returned to its more normal, relatively clean condition. For the first nine months of FY 2011, the division's sales increased 15% over the prior year to $64,226,000.

The growth for the Food Safety Division was broad-based across multiple market segments and product lines for the quarter and on a year-to-date basis. Sales of capital equipment and disposable vials associated with Neogen's Soleris® general microbial detection system exhibited strong growth in the quarter. The Soleris system allows for the accurate detection of spoilage organisms, such as yeast and mold, in much less time than traditional methods.

Scotland-based Neogen Europe continued to experience strong growth, up 16% in the quarter, as Neogen's food safety products furthered market share gains throughout the European Union. The company's Mexican subsidiary recorded an 87% sales increase compared to the prior year quarter, and Neogen's new subsidiary in Brazil also experienced strong revenue growth in the quarter.

Neogen's enhanced Reveal® line of tests for foodborne pathogens, including Salmonella, Listeria, and E. coli O157:H7, continued its sales growth, with each test recording sizable sales increases in the quarter. Sales of Neogen's enhanced BetaStar® test to detect antibiotic residues in milk continued their rapid increase.

Neogen Corporation develops and markets products dedicated to food and animal safety. The company's Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen's Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides.NEOGEN CORPORATION UNAUDITED SUMMARIZED CONSOLIDATED OPERATING DATA(In thousands, except for per share and percentages)Quarter ended
Feb. 28Nine months ended
Feb. 282011201020112010RevenueFood Safety



$55,639Animal Safety



45,791Total revenue42,23533,833129,088101,430Cost of sales



48,177Gross margin



53,253Other expensesSales & marketing






9,473Research & development



4,687Total other expenses



33,332Operating income



19,921Other income (expense)



66Income before tax



19,987Income tax



7,100Net income$4,943$3,881$16,878$12,887Net income per diluted share$0.21$0.17$0.71$0.56Other information:Shares to calculate per share



23,013Depreciation & amortization



$3,147Interest income



68Gross margin (% of sales)



52.5%Operating income (% of sales)



19.6%Revenue increase vs. FY 2010



-Net income increase vs. FY 2010



-NEOGEN CORPORATION UNAUDITED SUMMARIZED CONSOLIDATED BALANCE SHEET DATA(In thousands)Feb. 28May 3120112010AssetsCurrent assetsCash & investments


$22,806Accounts receivable




31,316Other current assets


4,465Total current assets


86,020Property & equipment


19,180Goodwill & other assets


75,033Total assets


$180,233Liabilities & Stockholders' EquityCurrent liabilities


$17,033Long-term debt


-Other long-term liabilities


10,147Stockholders' equity-shares outstanding23,190 in Feb. & 22,625 in May


153,053Total liabilities & stockholders' equity


$180,233Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's most recently filed Form 10-K.


SOURCE Neogen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Neogens Rapid Test for Salmonella enteritidis Receives FDA Approval
2. Neogen Names Quinlan as CFO
3. Neogen Reports 33% Increase in Net Income
4. Neogen Corporation Announces 2nd Quarter Results Conference Call
5. Neogens Rapid Test for Salmonella enteritidis Receives AOAC Approval
6. NeoGenomics Schedules its Q2 2010 Earnings Release for July 29, 2010
7. NeoGenomics to Present at Noble Financials 6th Annual Equity Conference on Monday, June 7th
8. Neogen Corporation Announces 3rd Quarter Results Conference Call
9. Neogen Reports 18% Increase in Net Income
10. Richard T. Crowder Joins Neogens Board of Directors
11. Neogen Announces 3 for-2 Stock Split
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded coverage of ... newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and ... synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates the market ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):